{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:19:40Z","timestamp":1777119580450,"version":"3.51.4"},"reference-count":70,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Introduction: Glioblastoma (GBM) patients have a 20\u201330 incidence of venous thromboembolic events. EGFR is a widely used prognostic marker for many cancers. Recent lung cancer studies have described relationships between EGFR amplification and an increased incidence of thromboembolic complications. We aim to explore this relationship in glioblastoma patients. Methods: Two hundred ninety-three consecutive patients with IDH wild-type GBM were included in the analysis. The amplification status of EGFR was measured using fluorescence in situ hybridization (FISH). Centromere 7 (CEP7) expression was recorded to calculate the EGFR-to-CEP7 ratio. All data were collected retrospectively through chart review. Molecular data were obtained through the surgical pathology report at the time of biopsy. Results: There were 112 subjects who were EGFR-amplified (38.2%) and 181 who were non-amplified (61.8%). EGFR amplification status was not significantly correlated with VTE risk overall (p = 0.2001). There was no statistically significant association between VTE and EGFR status after controlling for Bevacizumab therapy (p = 0.1626). EGFR non-amplified status was associated with an increased VTE risk in subjects greater than 60 years of age (p = 0.048). Conclusions: There was no significant difference in occurrence of VTE in patients with glioblastoma, regardless of EGFR amplification status. Patients older than 60 years of age with EGFR amplification experienced a lower rate of VTE, contrary to some reports on non-small-cell lung cancer linking EGFR amplification to VTE risk.<\/jats:p>","DOI":"10.3390\/curroncol30050373","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:36:59Z","timestamp":1683859019000},"page":"4946-4956","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-3396","authenticated-orcid":false,"given":"Brandon","family":"Kaye","sequence":"first","affiliation":[{"name":"Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assad","family":"Ali","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-8275","authenticated-orcid":false,"given":"Raphael Augusto","family":"Correa Bastianon Santiago","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-1233","authenticated-orcid":false,"given":"Bilal","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Isidor","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hany","family":"Awad","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadmahdi","family":"Sabahi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Obrzut","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badih","family":"Adada","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surabhi","family":"Ranjan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Borghei-Razavi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Florida, Department of Neurosurgery, Weston, FL 33331, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref_1","unstructured":"De Vleeschouwer, S. (2022, December 26). Current Standards of Care in Glioblastoma Therapy, Glioblastoma, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK469987\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11060-015-1805-2","article-title":"Venous thromboembolism (VTE) and glioblastoma","volume":"124","author":"Mandel","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Wojtukiewicz, M.Z., Mysliwiec, M., Matuszewska, E., Sulkowski, S., Zimnoch, L., Politynska, B., Wojtukiewicz, A.M., Tucker, S.C., and Honn, K.V. (2021). Imbalance in Coagulation\/Fibrinolysis Inhibitors Resulting in Extravascular Thrombin Generation in Gliomas of Varying Levels of Malignancy. Biomolecules, 11.","DOI":"10.3390\/biom11050663"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E","article-title":"The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review","volume":"89","author":"Marras","year":"2000","journal-title":"Cancer"},{"key":"ref_5","first-page":"325","article-title":"Pancreatic cancer and thromboembolic disease, 150 years after Trousseau","volume":"4","author":"Ansari","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.blre.2015.07.001","article-title":"The prothrombotic activity of cancer cells in the circulation","volume":"30","author":"Mitrugno","year":"2016","journal-title":"Blood Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjc.6605883","article-title":"Hospitalisation for venous thromboembolism in cancer patients and the general population: A population-based cohort study in Denmark, 1997\u20132006","volume":"103","author":"Pedersen","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv73","DOI":"10.1093\/neuonc\/nos197","article-title":"Thromboembolic disease in patients with high-grade glioma","volume":"14","author":"Perry","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_11","first-page":"e2678","article-title":"Risk of Venous Thromboembolism in Glioblastoma Patients","volume":"10","author":"Lim","year":"2018","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.wneu.2018.04.022","article-title":"Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance","volume":"116","author":"Noch","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","article-title":"Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide","volume":"10","author":"Hegi","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","article-title":"Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter\u2014Still a dilemma?","volume":"17","author":"Hegi","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.21873\/invivo.12881","article-title":"Determination of IDH1, IDH2, MGMT, TERT and ATRX Gene Mutations in Glial Tumors","volume":"36","author":"Yaltirik","year":"2022","journal-title":"In Vivo"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","article-title":"Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease","volume":"96","author":"Chen","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 9.","DOI":"10.3390\/cancers9050052"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/mdi006","article-title":"Impact of EGFR expression on colorectal cancer patient prognosis and survival","volume":"16","author":"Spano","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00204-015-1524-7","article-title":"Role of EGFR mutations in lung cancers: Prognosis and tumor chemosensitivity","volume":"89","author":"Suda","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1158\/0008-5472.CAN-04-1945","article-title":"Prognostic relevance of gene amplifications and complications in breast cancer","volume":"64","author":"Schraml","year":"2004","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"562798","DOI":"10.3389\/fmolb.2020.562798","article-title":"Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy","volume":"7","author":"Zhang","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: Recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11060-019-03298-6","article-title":"Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma","volume":"145","author":"Hoffman","year":"2019","journal-title":"J. Neuro-Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11060-019-03364-z","article-title":"EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?","volume":"146","author":"Armocida","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0360-3016(01)02699-2","article-title":"PAI-1 and EGFR expression in adult glioma tumors: Toward a molecular prognostic classification","volume":"52","author":"Muracciole","year":"2002","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0049-3848(12)70015-4","article-title":"Oncogenic regulation of tissue factor and thrombosis in cancer","volume":"129","author":"Anand","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.21037\/atm.2019.12.24","article-title":"The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism","volume":"7","author":"Wang","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jth.15215","article-title":"Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study","volume":"19","author":"Roopkumar","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11060-019-03102-5","article-title":"EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma","volume":"142","author":"Hovinga","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14698","DOI":"10.1038\/srep14698","article-title":"Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: A Systematic Review and Meta-Analysis","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/2152-7806.90696","article-title":"Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of Schwannoma (2000\u20132008): Findings of a multicenter Australian study","volume":"2","author":"Dobes","year":"2011","journal-title":"Surg. Neurol. Int."},{"key":"ref_36","first-page":"e8195","article-title":"Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population","volume":"12","author":"Grech","year":"2020","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-0034-1370791","article-title":"Thrombosis in brain tumors","volume":"40","author":"Jo","year":"2014","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.thromres.2015.09.006","article-title":"Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma","volume":"136","author":"Verso","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1158\/0008-5472.CAN-08-1547","article-title":"Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD\/activator protein-1 transcriptional activity","volume":"69","author":"Rong","year":"2009","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2013.10.042","article-title":"Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study","volume":"133","author":"Weng","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2009-10-250639","article-title":"Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells","volume":"116","author":"Magnus","year":"2010","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/neuonc\/noac204","article-title":"EGFR, the Lazarus target for precision oncology in glioblastoma","volume":"24","author":"Lin","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40248-017-0097-0","article-title":"Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma","volume":"12","author":"Davidsson","year":"2017","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_46","unstructured":"Shahzad, H., and Datta, D. (2017). B80-L. General Thoracic Oncology, American Thoracic Society. American Thoracic Society International Conference Abstracts."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.lungcan.2021.05.019","article-title":"Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis","volume":"157","author":"Zhu","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100742","DOI":"10.1016\/j.esmoop.2022.100742","article-title":"Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations","volume":"7","author":"Wang","year":"2022","journal-title":"ESMO Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.thromres.2016.10.020","article-title":"A systematic review of biomarkers for the prediction of thromboembolism in lung cancer\u2014Results, practical issues and proposed strategies for future risk prediction models","volume":"148","author":"Alexander","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1215\/15228517-2006-035","article-title":"Venous thromboembolism and survival in patients with high-grade glioma","volume":"9","author":"Simanek","year":"2007","journal-title":"Neuro Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/ene.15404","article-title":"Venous thromboembolic events in glioblastoma patients: An epidemiological study","volume":"29","author":"Eisele","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kapteijn, M.Y., Zwaan, S., ter Linden, E., Laghmani, E.H., van den Akker, R.F.P., Rondon, A.M.R., van der Zanden, S.Y., Neefjes, J., Versteeg, H.H., and Buijs, J.T. (2023). Temozolomide and Lomustine Induce Tissue Factor Expression and Procoagulant Activity in Glioblastoma Cells In Vitro. Cancers, 15.","DOI":"10.3390\/cancers15082347"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.wneu.2017.12.139","article-title":"High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients","volume":"112","author":"Natsumeda","year":"2018","journal-title":"World Neurosurg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3171\/2018.7.JNS181175","article-title":"Venous thromboembolic events in patients undergoing craniotomy for tumor resection: Incidence, predictors, and review of literature","volume":"132","author":"Rinaldo","year":"2019","journal-title":"J. Neurosurg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e914","DOI":"10.1161\/CIR.0000000000000769","article-title":"Call to Action to Prevent Venous Thromboembolism in Hospitalized Patients: A Policy Statement From the American Heart Association","volume":"141","author":"Henke","year":"2020","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients with EGFR-Mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00062752-199603050-00008","article-title":"Tissue factor in cancer angiogenesis and metastasis","volume":"3","author":"Ruf","year":"1996","journal-title":"Curr. Opin. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2004-822968","article-title":"Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy","volume":"30","author":"Yu","year":"2004","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10068","DOI":"10.1158\/0008-5472.CAN-08-2067","article-title":"Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: Effect on tumor initiation and angiogenesis","volume":"68","author":"Milsom","year":"2008","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1073\/pnas.0804543106","article-title":"Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR","volume":"106","author":"Meehan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","first-page":"803","article-title":"Comparative study analyzing survival and safety of bevacizumab\/carboplatin\/paclitaxel and cisplatin\/pemetrexed in chemotherapy-na\u00efve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation","volume":"6","author":"Kader","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40261-019-00757-w","article-title":"Bevacizumab Plus Direct Oral Anticoagulant Therapy in Ovarian Cancer Patients with Distal Deep Vein Thrombosis","volume":"39","author":"Komiyama","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1212\/WNL.0000000000011414","article-title":"Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype","volume":"96","author":"Diaz","year":"2021","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer\u2014A cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12931-018-0791-2","article-title":"Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer","volume":"19","author":"Dou","year":"2018","journal-title":"Respir. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2018.05.004","article-title":"Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis","volume":"167","author":"Young","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_69","first-page":"e83","article-title":"Anti-EGFR monoclonal antibodies increase the risk of Pulmonary Embolism in Cancer Patients. a systematic review and meta-analysis","volume":"37","author":"Miroddi","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1536\/ihj.21-507","article-title":"Cardiovascular Complications by EGFR Tyrosine Kinase Inhibitors in Patients with Lung Cancer","volume":"62","author":"Kimura","year":"2021","journal-title":"Int. Heart J."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/373\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:33:25Z","timestamp":1760124805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["curroncol30050373"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30050373","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}